

Inventiva’s confirms the success of its IPO. Over-allotment option partially exercised

Total size of the offering increased to around €48.5 million


Details of the stabilization transactions

Daix (France), March 17, 2017 – Inventiva announces today the partial exercise of the over-allotment option in connection with its initial public offering on Euronext Paris’ regulated market.

On March 16, 2017, Société Générale, acting on behalf of the underwriters, partially exercised the over-allotment option in respect of 55,337 additional new shares, raising a total of €470,364.50 at the offering price of €8.50 per share.

Accordingly, after partial exercise of the over-allotment option, the total number of Inventiva’s ordinary shares offered for sale in connection with its IPO stands at 5,706,577, representing 36% of its capital, thereby increasing the size of the offering to around €48.5 million. Settlement and delivery of the new shares issued through partial exercise of the over-allotment option will take place on March 20, 2017.

Following the IPO and the exercise of the over-allotment option, Inventiva’s share capital and voting rights break down as follows:



In its role as stabilization agent, Société Générale states that it has entered into stabilization transactions for a total of 227,225 Inventiva shares (FR0013233012) offered for sale in connection with its initial public offering.

The stabilization transactions commenced on February 15, 2017.

The final transactions were completed on March 14, 2017.

The stabilization transactions between February 15, 2017 and March 14, 2017 took place within the following price ranges:

Date	Lowest price	Highest price
02/15/2017	8.50	8.50
02/16/2017	8.50	8.50
02/17/2017	7.98	8.30
02/20/2017	8.00	8.30
02/21/2017	8.20	8.32
02/22/2017	8.24	8.34
02/23/2017	8.25	8.35
02/24/2017	8.03	8.29
02/27/2017	8.20	8.29
02/28/2017	8.25	8.35
03/01/2017	8.25	8.35
03/02/2017	8.22	8.50
03/03/2017	8.38	8.45
03/07/2017	8.41	8.41
03/08/2017	8.50	8.50
03/09/2017	8.49	8.50
03/10/2017	8.37	8.41
03/13/2017	8.42	8.42
03/14/2017	8.42	8.50

Other information

- Issuer's name: Inventiva
- Issuer's LEI: 969500I9Y690B3FZW590
- Investment service provider's name: Société Générale
- Investment service provider's LEI: O2RNE8IBXP4R0TD8PU41
- Financial instrument classification: Equity
- Company name: INVENTIVA
- ISIN Code: FR0013233012
- Ticker: IVA
- Compartment: C
- Sector: 4573 – Biotechnology

Financial intermediaries



*Global Coordinator
Joint-Lead Manager and Joint-Bookrunner*



Joint-Lead Manager and Joint-Bookrunner

Availability of the prospectus

On February 1, 2017, the French Autorité des Marchés Financiers (“**AMF**”) approved the French language prospectus relating to Inventiva’s initial public offering in France by granting visa no. 17-048 (the “**Prospectus**”), consisting of the « *Document de Base* » filed on July 8, 2016 under n° I.16-066, and its update submitted on January 12, 2017 under n° D.16-0535-A01 and a securities note (*note d’opération*) (including a Prospectus summary). For the purpose of the offering in France, copies of the Prospectus are available free of charge from Inventiva (50, rue de Dijon, 21121 Daix, France) and on the websites of the Company (www.inventivapharma.com) and the AMF (www.amf-france.org).

Risk factors

Inventiva draws the attention of investors on the "Risk Factors" section of chapter 4 of the Document de Base, as completed in its update, and of chapter 2 of the securities note.

Contacts

Inventiva

Frédéric Cren
Chief Executive Officer
info@inventivapharma.com
+33 (0)3 80 44 75 00

NewCap

Julien Perez / Mathilde Bohin
Investor Relations
inventiva@newcap.eu
+33 (0)1 44 71 98 52

NewCap

Nicolas Merigeau / Arthur Rouillé
Media Relations
inventiva@newcap.eu
+33 (0)1 44 71 94 98

About Inventiva: www.inventivapharma.com

Inventiva is a biopharmaceutical company specialised in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

IVA337, its lead product, is an anti-fibrotic treatment with a strong action mechanism permitting the activation of all three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing in parallel, a second clinical product, IVA336, which is a clinical program for the treatment of three different forms of mucopolysaccharidosis (MPS I or Hurler-Sheie syndrome, MPS II or Hunter syndrome and MPS VI also known as Maroteaux-Lamy syndrome), as well as a preclinical stage oncology portfolio.

Inventiva benefits from two partnerships with world-leading research entities such as the Institut Curie. Two strategic partnerships have also been developed with AbbVie and Boehringer Ingelheim, making Inventiva eligible for preclinical,

This document may not be distributed, directly or indirectly, in the United States, Canada, Australia, or Japan.

clinical, regulatory and commercial milestone payments, in addition to royalties on the products resulting from these partnerships.

Inventiva employs over 100 highly qualified employees and owns state-of-the-art R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

Disclaimer

This announcement does not, and shall not, in any circumstances constitute a public offering nor an invitation to the public in France, in the United States or in any other jurisdiction in connection with any public offering.

The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

This announcement is an advertisement and not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and of the Council of November 4, 2003, as amended (the "**Prospectus Directive**").

With respect to the member States of the European Economic Area, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant member State other than France. As a result, the securities may not and will not be offered in any relevant member State other than France except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive, or under any other circumstances which do not require the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive.

This document may not be distributed, directly or indirectly, in the United States. This document is not an offer of securities for sale nor the solicitation of an offer to purchase securities in the United States or any other jurisdiction where such offer may be restricted. Securities may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the "**Securities Act**"), or an exemption from registration. The shares of the Company have not been and will not be registered under the Securities Act, and the Company does not intend to make a public offer of its securities in the United States.

This document is only being distributed to, and is only directed at, persons that (i) are located outside the United Kingdom, (ii) are "investment professionals" falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "**Order**"), (iii) are persons falling within Article 49(2)(a) to (d) ("*high net worth companies, unincorporated associations, etc.*") of the Order, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Article 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This document may not be distributed, directly or indirectly, in the United States, Canada, Australia, or Japan.